REGENXBIO Inc. Available-for-sale Securities, Gross Realized Gain (Loss)
REGENXBIO Inc. (RGNX) reported Available-for-sale Securities, Gross Realized Gain (Loss) of $7.08 million for the 6-month period ending 2020-06-30, per its 10-Q filed 2020-08-06.
Discontinued › Income Statement › Other Income
us-gaap:AvailableForSaleSecuritiesGrossRealizedGainLossNet · last filed 2020-08-06
- REGENXBIO Inc. available-for-sale securities, gross realized gain (loss) for the quarter ending 2020-06-30 was -$10.00K.
- REGENXBIO Inc. available-for-sale securities, gross realized gain (loss) for the quarter ending 2020-03-31 was $7.08M.
- REGENXBIO Inc. available-for-sale securities, gross realized gain (loss) for the quarter ending 2019-12-31 was $5.97M.
- REGENXBIO Inc. available-for-sale securities, gross realized gain (loss) for the quarter ending 2018-12-31 was -$24.00K.
- REGENXBIO Inc. available-for-sale securities, gross realized gain (loss) for fiscal 2019 was $5.99M.
- REGENXBIO Inc. available-for-sale securities, gross realized gain (loss) for fiscal 2018 was -$39.00K, a 108.14% decline from fiscal 2017.
- REGENXBIO Inc. available-for-sale securities, gross realized gain (loss) for fiscal 2017 was $479.00K.
- REGENXBIO Inc. available-for-sale securities, gross realized gain (loss) for fiscal 2015 was $0.00.
| Period end | Available-for-sale Securities, Gross Realized Gain (Loss) 3 month | Available-for-sale Securities, Gross Realized Gain (Loss) 6 month | Available-for-sale Securities, Gross Realized Gain (Loss) 9 month | Available-for-sale Securities, Gross Realized Gain (Loss) 12 month |
|---|---|---|---|---|
| 2020-06-30 | -$10.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2020-08-06 | $7.08M 10-Q · filed 2020-08-06 | $13.04M derived: sum of 3 quarters · filed 2020-08-06 | |
| 2020-03-31 | $7.08M 10-Q · filed 2020-05-07 | $13.05M derived: sum of 2 quarters · filed 2020-05-07 | ||
| 2019-12-31 | $5.97M derived: 10-K 12 month − 10-Q 9 month · filed 2020-02-26 | $5.99M 10-K · filed 2020-02-26 | ||
| 2019-09-30 | $20.00K 10-Q · filed 2019-11-05 | |||
| 2018-12-31 | -$24.00K derived: 10-K 12 month − 10-Q 9 month · filed 2020-02-26 | -$39.00K 10-K · filed 2020-02-26 | ||
| 2018-09-30 | -$15.00K 10-Q · filed 2019-11-05 | |||
| 2017-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2020-02-26 | -$1.00K derived: sum of 2 quarters · filed 2020-02-26 | -$1.00K derived: sum of 3 quarters · filed 2020-02-26 | $479.00K 10-K · filed 2020-02-26 |
| 2017-09-30 | -$1.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2018-11-07 | -$1.00K derived: sum of 2 quarters · filed 2018-11-07 | $479.00K 10-Q · filed 2018-11-07 | |
| 2017-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2018-08-08 | $480.00K 10-Q · filed 2018-08-08 | ||
| 2017-03-31 | $480.00K 10-Q · filed 2018-05-08 | |||
| 2016-09-30 | $20.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2017-11-08 | $20.00K derived: sum of 2 quarters · filed 2017-11-08 | $20.00K 10-Q · filed 2017-11-08 | $20.00K derived: sum of 4 quarters · filed 2017-11-08 |
| 2016-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2016-08-09 | $0.00 10-Q · filed 2016-08-09 | $0.00 derived: sum of 3 quarters · filed 2016-08-09 | |
| 2016-03-31 | $0.00 10-Q · filed 2016-05-05 | $0.00 derived: sum of 2 quarters · filed 2016-05-05 | ||
| 2015-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2016-03-03 | $0.00 10-K · filed 2016-03-03 | ||
| 2015-09-30 | $0.00 10-Q · filed 2015-11-05 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Entera Bio Ltd. (ENTX) | $0.485B | ||
| Tectonic Therapeutic, Inc. (TECX) | United States | $0.469B | -7.68 |
| Autolus Therapeutics plc (AUTL) | $0.506B | -1.52 | |
| Eikon Therapeutics, Inc. (EIKN) | United States | $0.446B | |
| Kyverna Therapeutics, Inc. (KYTX) | United States | $0.434B | -3.60 |
| Editas Medicine, Inc. (EDIT) | United States | $0.424B | -4.29 |
| Scribe Therapeutics, Inc. (SCTX) | United States | $0.410B | |
| Prime Medicine, Inc. (PRME) | United States | $0.557B | -3.54 |
| Zura Bio Ltd (ZURA) | $0.398B | -6.56 | |
| Surrozen, Inc./DE (SRZN) | United States | $0.395B |